Dearborn Partners LLC Buys 400 Shares of Novo Nordisk A/S (NYSE:NVO)

Dearborn Partners LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,972 shares of the company’s stock after acquiring an additional 400 shares during the period. Dearborn Partners LLC’s holdings in Novo Nordisk A/S were worth $342,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of NVO. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the 3rd quarter worth about $28,000. Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares during the last quarter. Sound Income Strategies LLC increased its position in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after acquiring an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.0 %

Shares of NYSE NVO opened at $78.14 on Wednesday. Novo Nordisk A/S has a twelve month low of $73.50 and a twelve month high of $148.15. The stock has a market cap of $350.63 billion, a price-to-earnings ratio of 23.75, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company’s fifty day moving average is $84.61 and its 200-day moving average is $104.04.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Wall Street Analyst Weigh In

Several research firms have issued reports on NVO. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.